Hyundai Pharm (004310) - Total Assets
Based on the latest financial reports, Hyundai Pharm (004310) holds total assets worth ₩224.31 Billion KRW (≈ $152.01 Million USD) as of February 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hyundai Pharm cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Hyundai Pharm - Total Assets Trend (2010–2025)
This chart illustrates how Hyundai Pharm's total assets have evolved over time, based on quarterly financial data. See 004310 net assets for net asset value and shareholders' equity analysis.
Hyundai Pharm - Asset Composition Analysis
Current Asset Composition (November 2025)
Hyundai Pharm's total assets of ₩224.31 Billion consist of 49.5% current assets and 50.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.5% |
| Accounts Receivable | ₩42.27 Billion | 25.9% |
| Inventory | ₩32.59 Billion | 20.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.31 Billion | 4.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Hyundai Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Hyundai Pharm.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hyundai Pharm's current assets represent 49.5% of total assets in 2025, a decrease from 59.8% in 2010.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, down from 8.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 25.9% of total assets.
Hyundai Pharm Competitors by Total Assets
Key competitors of Hyundai Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Hyundai Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.28 | 1.30 | 1.52 |
| Quick Ratio | 0.79 | 0.77 | 1.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩21.74 Billion | ₩18.36 Billion | ₩26.56 Billion |
Hyundai Pharm - Advanced Valuation Insights
This section examines the relationship between Hyundai Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.11 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.4% |
| Total Assets | ₩163.22 Billion |
| Market Capitalization | $112.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hyundai Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hyundai Pharm's assets grew by 4.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hyundai Pharm (2010–2025)
The table below shows the annual total assets of Hyundai Pharm from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-11-30 | ₩163.22 Billion ≈ $110.61 Million |
+4.36% |
| 2024-11-30 | ₩156.40 Billion ≈ $105.99 Million |
+1.14% |
| 2023-11-30 | ₩154.63 Billion ≈ $104.79 Million |
-14.64% |
| 2022-11-30 | ₩181.16 Billion ≈ $122.77 Million |
+10.56% |
| 2021-11-30 | ₩163.86 Billion ≈ $111.04 Million |
+4.04% |
| 2020-11-30 | ₩157.50 Billion ≈ $106.74 Million |
+8.27% |
| 2019-11-30 | ₩145.47 Billion ≈ $98.59 Million |
-8.39% |
| 2018-11-30 | ₩158.80 Billion ≈ $107.62 Million |
+2.71% |
| 2017-11-30 | ₩154.62 Billion ≈ $104.78 Million |
+2.70% |
| 2016-11-30 | ₩150.55 Billion ≈ $102.02 Million |
+4.98% |
| 2013-11-30 | ₩143.40 Billion ≈ $97.18 Million |
-4.34% |
| 2012-11-30 | ₩149.90 Billion ≈ $101.59 Million |
-4.49% |
| 2011-11-30 | ₩156.95 Billion ≈ $106.36 Million |
+19.82% |
| 2010-11-30 | ₩130.98 Billion ≈ $88.76 Million |
-- |
About Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, a… Read more